Current Report Filing (8-k)
March 17 2020 - 05:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 17,
2020
KRAIG BIOCRAFT LABORATORIES, INC.
(Exact
name of registrant as specified in its charter)
Wyoming |
|
333-146316 |
|
83-0458707 |
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
2723
South State St. Suite 150
Ann
Arbor, Michigan 48104
(Address of principal executive offices, including Zip
Code)
(734)
619-8066
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
[ ] |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
None |
|
- |
|
- |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (?230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company [ ]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[ ]
Item
7.01: Regulation FD Disclosure
On
February 27, 2020, the Company announced a press conference it was
going to hold on March 19, 2020. Due to continued uncertainty
surrounding the outbreak of the COVID-19 virus, the Company is
postponing such press conference to April 16, 2020. On March 17,
2020,the Company issued a press release announcing the new date of
the press conference. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
The
information reported under this Item 7.01 of Form 8-K, including
Exhibit 99.1, is being furnished and shall not be deemed to be
“filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of such section, nor shall such
information be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such
filing.
Item
8.01 Other Events.
To
the extent required, the information included in Item 7.01 of this
Current Report on Form 8-K is incorporated in this Item 8.01 by
reference.
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
March 17, 2020
|
KRAIG BIOCRAFT LABORATORIES, INC. |
|
|
|
|
By: |
/s/
Kim Thompson |
|
|
Kim
Thompson |
|
|
Chief
Executive Officer, |
|
|
Chief Financial
Officer and Director |